DDInter777 DDInter1082
Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Fosamprenavir {u} (Compound) resembles {v} (Compound) Darunavir
Fosamprenavir {u} (Compound) binds {v} (Gene) CYP3A4
Fosamprenavir {u} (Compound) causes {v} (Side Effect) Neutropenia
Fosamprenavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Fosamprenavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clarithromycin
Fosamprenavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gadobenic acid
Fosamprenavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rivaroxaban
Fosamprenavir {u} may lead to a major life threatening interaction when taken with {v} Salmeterol
Fosamprenavir {u} may lead to a major life threatening interaction when taken with {v} Fedratinib
Fosamprenavir (Compound) resembles Darunavir (Compound)
Fosamprenavir (Compound) binds CYP3A4 (Gene)
Fosamprenavir (Compound) causes Neutropenia (Side Effect)
Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Gadobenic acid
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban
Fosamprenavir may lead to a major life threatening interaction when taken with Salmeterol
Fosamprenavir may lead to a major life threatening interaction when taken with Fedratinib